Eisai | GenomeWeb

Eisai

Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.

The companies said they aim to discover next-generation tests that will enable early diagnosis of dementia, as well as treatment selection and monitoring.

Under the terms of the deal, Oncodesign will conduct in vivo pharmacology studies, while Eisai will do gene expression analysis.

Given its interest in developing treatments for Alzheimer's disease (AD), Japanese drugmaker Eisai is exploring the potential of plasma-based microRNAs to serve as biomarkers for the disease.

Seegene and Eidia, the in vitro diagnostics subsidiary of Japanese pharmaceutical firm Eisai, have entered into a collaborative agreement to bring new multiplex molecular diagnostic tests to Japan.

NEW YORK (GenomeWeb News) – Seegene announced today that it has signed an agreement with Eidia to market the firm's molecular diagnostic products in Japan.

Epizyme this week announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

NEW YORK (GenomeWeb News) — Epizyme today announced a collaboration with Eisai and Roche to develop an in vitro, PCR-based companion diagnostic test to help treat genetically defined lymphomas.

NEW YORK (GenomeWeb News) – Japanese drug firm Eisai and its diagnostics subsidiary Eidia said today that they are dissolving their diagnostics R&D subsidiary, Palma Bee'Z Research Institute, as part of the Eisai Group's transformation of its in vitro diagnostics development operations.

NEW YORK (GenomeWeb News) – Foundation Medicine today said that it has signed a multi-year alliance with Eisai to conduct genomic profiling and diagnostic discovery for an oncology therapeutic candidate being developed by the Japanese drug firm.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.